Indivior Pharmaceuticals (INDV) Depreciation & Amortization (CF) (2024 - 2026)

Indivior Pharmaceuticals' Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 33.33% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $9.0 million (down 43.75% YoY), while the FY2025 annual figure was $10.0 million, down 37.5% from the prior year.
• Depreciation & Amortization (CF) was $2.0 million for Q1 2026 at Indivior Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.0 million in Q1 2024 to a low of $2.0 million in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $3.3 million across 3 years, with a median of $3.0 million in 2025.
• Biggest YoY gain for Depreciation & Amortization (CF) was 25.0% in 2025; the steepest drop was 60.0% in 2025.
• A 3-year view of Depreciation & Amortization (CF) shows it stood at $5.0 million in 2024, then tumbled by 60.0% to $2.0 million in 2025, then changed by 0.0% to $2.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.